Mepolizumab for eosinophilic chronic sinusitis with nasal polyposis: real-life experience

Kassem, F; Cohen-Confino, R; Meir‐Shafrir, Keren; Lachover‐Roth, Idit; Cohen‐Engler, Anat; Nageris, Ben I.; Rosman, Yossi

doi:10.4193/rhin20.416

Cited by 5 publications

(4 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The effects of MEP were studied first in randomized controlled trials (RCT) [ 16 , 17 , 18 ] and then in real-life studies [ 19 , 20 , 21 ], confirming its efficacy and providing useful information on some aspects such as its pharmacoeconomics and the effect on comorbidities [ 22 , 23 , 24 , 25 ]. The effect of MEP was clearly demonstrated in patients with eosinophilic severe asthma with a cell count greater than 300/μL in the 12 months prior to the drug’s administration and at least 150 at the time of the first dose.…”

Section: Introductionmentioning

confidence: 99%

Long-Term Efficacy of Mepolizumab at 3 Years in Patients with Severe Asthma: Comparison with Clinical Trials and Super Responders

Bagnasco,

Nicola,

Testino

et al. 2023

Biomedicines

View full text Add to dashboard Cite

The efficacy mepolizumab in severe asthmatic patients is proven in the literature. Primarily to study the effect of mepolizumab on exacerbations, steroid dependence, and the continuation of efficacy in the long term. Secondarily to evaluate the effect of the drug on nasal polyps. Analyzing data from SANI (Severe Asthma Network Italy) clinics, we observed severe asthmatic patients treated with mepolizumab 100 mg/4 weeks, for a period of 3 years. 157 patients were observed. Exacerbations were reduced from the first year (−84.6%) and progressively to 90 and 95% in the second and third ones. Steroid-dependent patients decreased from 54% to 21% and subsequently to 11% in the second year and 6% in the third year. Patients with concomitant nasal polyps, assessed by SNOT-22, showed a 49% reduction in value from baseline to the third year. The study demonstrated the long-term efficacy of mepolizumab in a real-life setting.

show abstract

Section: Introductionmentioning

confidence: 99%

Long-Term Efficacy of Mepolizumab at 3 Years in Patients with Severe Asthma: Comparison with Clinical Trials and Super Responders

Bagnasco,

Nicola,

Testino

et al. 2023

Biomedicines

View full text Add to dashboard Cite

show abstract

“…Real-life data has also suggested that mepolizumab is equally effective in patients with and without certain comorbidities such as nasal polyposis [ 59 , 60 , 61 , 62 , 63 , 64 , 65 ], also indicating that patients with this condition have a better response to the drug [ 66 ].…”

Section: T2 Targeted Therapies In Asthmamentioning

confidence: 99%

Personalized and Precision Medicine in Asthma and Eosinophilic Esophagitis: The Role of T2 Target Therapy

Bagnasco,

Savarino,

Yacoub

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

The role of type 2 inflammation has been progressively associated with many diseases, including severe asthma, atopic dermatitis, nasal polyposis, eosinophilic granulomatosis with polyangiitis, and, recently, eosinophilic esophagitis. Despite this, the association between asthma and esophagitis is still poorly known, and this is probably because of the low prevalence of each disease and the even lower association between them. Nonetheless, observations in clinical trials and, subsequently, in real life, have allowed researchers to observe how drugs acting on type 2 inflammation, initially developed and marketed for severe asthma, could be effective also in treating eosinophilic esophagitis. For this reason, clinical trials specifically designed for the use of drugs targeted to type 2 inflammation were also developed for eosinophilic esophagitis. The results of clinical trials are presently promising and envisage the use of biologicals that are also likely to be employed in the field of gastroenterology in the near future. This review focuses on the use of biologicals for type 2 inflammation in cases of combined severe asthma and eosinophilic esophagitis.

show abstract

“…Very recently, a comparative analysis of the efficacy of reported biologicals for CRSwNP based on the published data for phase 2 and 3 studies was published [81]. A direct comparison of the efficacy between dupilumab, mepolizumab [82], and omalizumab is challenging, given differences in inclusion criteria, outcome parameters, and time-points of analysis. However, consistent and major reduction of patient relevant and irrelevant outcome parameters are found in all studies with biologicals for CRSwNP, with most available data on dupilumab.…”

Section: Dupilumab Compared To Other Biologicalsmentioning

confidence: 99%

Dupilumab for the treatment of chronic rhinosinusitis with nasal polyposis

Fokkens¹,

Lans²,

Reitsma³

2021

Expert Opinion on Biological Therapy

View full text Add to dashboard Cite

Introduction: Chronic rhinosinusitis with nasal polyps (CRSwNP) affects 1-2.5% of the population and is associated with significant adverse effects on quality of life (QoL). CRSwNP is strongly correlated with (late onset) asthma with 30-70% of the CRSwNP patients having asthma. Health-care spending in rhinosinusitis is high, especially because of indirect costs. Areas covered: In the last years, the recognition of endotyping as an essential presumption to precision medicine has significantly changed the integrated care pathways in the treatment of chronic rhinosinusitis. Dupilumab is the first biological available for the treatment of CRswNP, since late 2019. Treatment with dupilumab results in a significant improvement of QoL (measured as SNOT-22), rhinosinusitis disease severity, symptoms of rhinosinusitis, and especially sense of smell, nasal polyp score, Lund-Mackay CT score, and asthma outcomes (ACQ5 and FEV1) compared to placebo. Expert opinion: At this moment, the high cost of the treatment requires careful patient selection and within the EUFOREA and EPOS2020 context, experts have tried to give guidance based on today's data. We now need trials evaluating which patients benefit most from treatment with biologicals and in which patients the treatment is cost-effective.

show abstract

Mepolizumab for eosinophilic chronic sinusitis with nasal polyposis: real-life experience

Cited by 5 publications

References 8 publications

Long-Term Efficacy of Mepolizumab at 3 Years in Patients with Severe Asthma: Comparison with Clinical Trials and Super Responders

Long-Term Efficacy of Mepolizumab at 3 Years in Patients with Severe Asthma: Comparison with Clinical Trials and Super Responders

Personalized and Precision Medicine in Asthma and Eosinophilic Esophagitis: The Role of T2 Target Therapy

Dupilumab for the treatment of chronic rhinosinusitis with nasal polyposis

Contact Info

Product

Resources

About